Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease
Li, Hong‐Dong , Funk, Cory C. , McFarland, Karen N. , Dammer, Eric B. , Allen, Mariet , Carrasquillo, Minerva M. , Levites, Yona , Chakrabarty, Paramita , Burgess, Jeremy D. , Wang, Xue , Seyfried, Nicholas T. , Lah, James J., Younkin, Steven G., Levey, Allan I. , Ertekin‐Taner, Nilüfer , Golde, Todd E. , Dammer, Eric B , Levey, Allan I , Carrasquillo, Minerva M. , Dickson, Dennis W. , Duong, Duc M , Omenn, Gilbert S. , Price, Nathan D.

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 984-1004

10.1002/alz.12254 | PMID 33480174 Get It

AbstractIntron retention (IR) has been implicated in the pathogenesis of complex diseases such as cancers; its association with Alzheimer's disease (AD) remains unexplored. We performed genome‐wide analysis of IR through integrating genetic, transcriptomic, and proteomic data of AD subjects and mouse models from the Accelerating Medicines Partnership‐Alzheimer's Disease project. We identified 4535 and 4086 IR events in 2173 human and 1736 mouse genes, respectively. Quantitation of IR enabled the identification of differentially expressed genes that conventional exon‐level approaches did not reveal. There were significant correlations of intron expression within innate immune genes, like HMBOX1, with AD in humans. Peptides with a high probability of translation from intron‐retained mRNAs were identified using mass spectrometry. Further, we established AD‐specific intron expression Quantitative Trait Loci, and identified splicing‐related genes that may regulate IR. Our analysis provides a novel resource for the search for new AD biomarkers and pathological mechanisms.
Modeling autosomal dominant Alzheimer's disease with machine learning
Luckett, Patrick H. , McCullough, Austin , Gordon, Brian A. , Strain, Jeremy F. , Flores, Shaney , Dincer, Aylin , Kuffner, Todd A. , Stern, Ari, Meeker, Karin L. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Oh, Hwamee , Swisher, Laura, Marcus, Daniel S. , Koudelis, Deborah, Joseph‐Mathurin, Nelly , Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Wang, Qing , Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Berman, Sarah , McCarthy, John Edward , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Wáng, Qīng , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 1005-1016

10.1002/alz.12259 | PMID 33480178 Get It

AbstractIntroductionMachine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease.MethodsLongitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non‐carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status.ResultsThe Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non‐carriers.DiscussionResults suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.
Determining mutational burden and signature using RNA-seq from tumor-only samples
Jessen, Erik , Liu, Yuanhang , Kocher, Jean-Pierre A., Jessen, Erik , Davila, Jaime , Wang, Chen

Mayo Clinic

No container title available | January 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.21641/v3 Get It

Abstract Background: Traditionally, mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing. The requirement of having both normal and tumor samples is not always feasible from a clinical perspective, and led us to investigate the efficacy of using RNA sequencing of only the tumor sample to determine the mutational burden and signatures, and subsequently molecular cause of the cancer. The potential advantages include reducing the cost of testing, and simultaneously providing information on the gene expression profile and gene fusions present in the tumor. Results: In this study, we devised supervised and unsupervised learning methods to determine mutational signatures from tumor RNA-seq data. As applications, we applied the methods to a training set of 587 TCGA uterine cancer RNA-seq samples, and examined in an independent testing set of 521 TCGA colorectal cancer RNA-seq samples. Both diseases are known associated with microsatellite instable high (MSI-H) and driver defects in DNA polymerase ɛ (POLɛ). From RNA-seq called variants, we found majority (>95%) are likely germline variants, leading to C>T enriched germline variants (dbSNP) widely applicable in tumor and normal RNA-seq samples. We found significant associations between RNA-derived mutational burdens and MSI/POLɛ status, and insignificant relationship between RNA-seq total coverage and derived mutational burdens. Additionally we found that over 80% of variants could be explained by using the COSMIC mutational signature-5, -6 and -10, which are implicated in natural aging, MSI-H, and POLɛ, respectively. For classifying tumor type, within UCEC we achieved a recall of 0.56 and 0.78, and specificity of 0.66 and 0.99 for MSI and POLɛ respectively. By applying learnt RNA signatures from UCEC to COAD, we were able to improve our classification of both MSI and POLɛ. Conclusions: Taken together, our work provides a novel method to detect RNA-seq derived mutational signatures with effective procedures to remove likely germline variants. It can leads to accurate classification of underlying driving mechanisms of DNA damage deficiency.
Construct Validation of the American Board of Anesthesiology’s APPLIED Examination for Initial Certification
Zhou, Yan , Chen, Dandan , Harman, Ann E., Isaak, Robert S. , Peterson-Layne, Cathleen, Macario, Alex, Fahy, Brenda G. , Wang, Ting , Sun, Huaping , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 21, 2021 | Volume: 133 | Issue: 1 | Pages: 226-232

10.1213/ane.0000000000005364 | PMID 33481404 Get It

BACKGROUND: The American Board of Anesthesiology administers the APPLIED Examination as a part of initial certification, which as of 2018 includes 2 components—the Standardized Oral Examination (SOE) and the Objective Structured Clinical Examination (OSCE). The goal of this study is to investigate the measurement construct(s) of the APPLIED Examination to assess whether the SOE and the OSCE measure distinct constructs (ie, factors). METHODS: Exploratory item factor analysis of candidates’ performance ratings was used to determine the number of constructs, and confirmatory item factor analysis to estimate factor loadings within each construct and correlation(s) between the constructs. RESULTS: In exploratory item factor analysis, the log-likelihood ratio test and Akaike information criterion index favored the 3-factor model, with factors reflecting the SOE, OSCE Communication and Professionalism, and OSCE Technical Skills. The Bayesian information criterion index favored the 2-factor model, with factors reflecting the SOE and the OSCE. In confirmatory item factor analysis, both models suggest moderate correlation between the SOE factor and the OSCE factor; the correlation was 0.49 (95% confidence interval [CI], 0.42-0.55) for the 3-factor model and 0.61 (95% CI, 0.54-0.64) for the 2-factor model. The factor loadings were lower for Technical Skills stations of the OSCE (ranging from 0.11 to 0.25) compared with those of the SOE and Communication and Professionalism stations of the OSCE (ranging from 0.36 to 0.50). CONCLUSIONS: The analyses provide evidence that the SOE and the OSCE measure distinct constructs, supporting the rationale for administering both components of the APPLIED Examination for initial certification in anesthesiology.
P234 Comparing the EndoRotor® resection device with continued ablation in treatment of refractory barrett’s oesophagus
Hussein, Mohamed , Sami, Sarmed S. , Lovat, Laurence , Haidry, Rehan, Wang, Kenneth T.

Mayo Clinic

Posters | January 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: A163.1-A163

10.1136/gutjnl-2020-bsgcampus.308 Get It

Frequent POLE-Driven Hypermutation in Ovarian Endometrioid Cancer Revealed by Mutational Signatures in RNA Sequencing
Chanana, Pritha , Sarangi, Vivekananda , Weroha, S. John , Guo, Ruifeng, Goode, Ellen, Huang, Yajue, Chen, Wang , Guo, Ruifeng , Guo, Ruifeng , Davila, Jaime , Fogarty, Zachary C.

Mayo Clinic

No container title available | January 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-145368/v1 Get It

Abstract Background: DNA polymerase epsilon (POLE) is encoded by the POLE gene, and POLE-driven tumors are characterized by high mutational rates. POLE-driven tumors are relatively common in endometrial and colorectal cancer, and their presence is increasingly recognized in ovarian cancer (OC) of endometrioid type. POLE-driven cases possess an abundance of TCT>TAT and TCG>TTG somatic mutations characterized by mutational signature 10 from the Catalog of Somatic Mutations in Cancer (COSMIC). By quantifying the contribution of COSMIC mutational signature 10 in RNA sequencing (RNA-seq) we set out to identify POLE-driven tumors in a set of unselected Mayo Clinic OC. Methods: Mutational profiles were calculated using expressed single-nucleotide variants (eSNV) in the Mayo Clinic OC tumors (n=195), The Cancer Genome Atlas (TCGA) OC tumors (n=419), and the Genotype-Tissue Expression (GTEx) normal ovarian tissues (n=84). Non-negative Matrix Factorization (NMF) of the mutational profiles inferred the contribution per sample of four distinct mutational signatures, one of which corresponds to COSMIC mutational signature 10. Results: In the Mayo Clinic OC cohort we identified six tumors with a predicted contribution from COSMIC mutational signature 10 of over five mutations per megabase. These six cases harbored known POLE hotspot mutations (P286R, S297F, V411L, and A456P) and were of endometrioid histotype (P=5e-04). These six tumors were hypermutated with a higher tumor mutation load (mean, 54.02 mutations per megabase) compared to non-POLE endometrioid OC cases (mean, 7.69 mutations per megabase; P=5e-04), and had an early onset (average age of patients at onset, 48.33 years) when compared to non-POLE endometrioid OC cohort (average age at onset, 60.13 years; P=.008). Samples from TCGA and GTEx had a low COSMIC signature 10 contribution (median 0.16 mutations per megabase; maximum 1.78 mutations per megabase) and carried no POLE hotspot mutations.Conclusions: From the largest cohort of RNA-seq from endometrioid OC to date (n=53), we identified six hypermutated samples likely driven by POLE (frequency, 11%). Our result suggests the clinical need to screen for POLE driver mutations in endometrioid OC, which can guide enrollment in immunotherapy clinical trials.
The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis
Ibilibor, Christine , Herrera, Jesús Fernández, Rivero, J. Ricardo, Wang, Hanzhang , Mansour, Ahmed M. , Svatek, Robert S. , Kaushik, Dharam , Farrell, Ann M, Psutka, Sarah P. , Herrera, Jesus, Farrell, Ann , Liss, Michael A. , Pruthi, Deepak Kumar

Mayo Clinic

Arab Journal of Urology | January 16, 2021 | Volume: 19 | Issue: 1 | Pages: 98-103

10.1080/2090598x.2021.1876289 | PMID 33763255 Get It

Total Shoulder Arthroplasty versus Reverse Total Shoulder Arthroplasty: Outcome Comparison in Osteoarthritis patients with or without Concurrent Rotator Cuff Deficiency
Long, Zeling , Huang, Tony Chieh‐Ting , Yu, Hanzhong, Wang, Yicun , Wang, Wanchun

Mayo Clinic

No container title available | January 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-146668/v1 Get It

Abstract BackgroundOsteoarthritis (OA) is a common shoulder disorder that impacts shoulder functions. Shoulder arthroplasty is often required to restore function and quality of life. Reverse total shoulder arthroplasty (RSA), which was originally designed mainly for irreparable rotator cuff damage, has gained popularity in recent years for the treatment of advanced shoulder OA instead of the clinically standard total shoulder arthroplasty (TSA). However, this RSA has some nonnegligible flaws such as higher complications rate and economic cost, not mention the following problems caused by irreversible physical structural damage. Therefore, the employment of RSA needs to be carefully considered.PurposeThis study aimed to compare TSA and RSA in OA patients with or without rotator cuff damage to better guide clinical decision making. We believe the radical use of RSA in patients without rotator cuff deficiency may cause more harm than good.Study designCross-sectional studyMethodsWe queried the Nationwide Inpatient Sample (NIS) database from 2011 to 2014 to collect information on OA patients who received TSA and RSA. Patients were divided into 2 groups of comparison according to the presence of rotator cuff deficiency and matched with propensity score analysis.Results A total of 57,156 shoulder arthroplasties were identified. RSA patients in the rotator cuff deficiency group had significant higher transfusion rates and longer hospital stays. RSA patients without rotator cuff deficiency had a statistically significantly higher number of implant-related mechanical complications, acute upper respiratory infections and postoperative pain. Overall, RSA incurred higher costs in both groups.ConclusionFor OA patients with rotator cuff deficiencies, RSA has its benefits as complication rates were comparable to TSA. For those patients without rotator cuff deficiencies, the use of RSA should be reconsidered as there were more complications with higher severity.
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
Nie, Wei , Gan, Lu , Wang, Xin , Gu, Kai , Qian, Fang-Fei, Hu, Min-Juan, Chen, Shi-Qing, Lü, Jun , Cao, Shu-Hui, Li, Jing-Wen, Zhang, Bo , Wang, Shu-Yuan, Li, Chang-Hui, Xu, Midie , Zhang, Xue-Yan, Zhong, Hua , Han, Bao-Hui , Gu, Kai, Zhang, Ding , Wang, Yue , Yang, Ping

Mayo Clinic

OncoImmunology | January 15, 2021 | Volume: 10 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1865670 | PMID 33537171 Get It

A 4‐minute solution for submillimeter whole‐brain T1ρ quantification
Zhu, Yanjie , Ying, Leslie , Qiu, Zhilang , Liu, Qiegen , Jia, Sen , Wang, Haifeng , Peng, Xi , Liu, Xin , Zheng, Hairong , Ying, Leslie , Wang, Haifeng , Peng, Xi , Liang, Dong , Liu, Yuanyuan

Mayo Clinic

Magnetic Resonance in Medicine | January 15, 2021 | Volume: 85 | Issue: 6 | Pages: 3299-3307

10.1002/mrm.28656 | PMID 33421224 Get It

PurposeTo develop a robust, accurate, and accelerated T1ρ quantification solution for submillimeter in vivo whole‐brain imaging.MethodsA multislice T1ρ mapping solution (MS‐T1ρ) was developed based on a two‐acquisition scheme using turbo spin echo with RF cycling to allow for whole‐brain coverage with 0.8‐mm in‐plane resolution. A compressed sensing–based fast imaging method, SCOPE, was used to accelerate the MS‐T1ρ acquisition time to a total scan time of 3 minutes 31 seconds. A phantom experiment was conducted to assess the accuracy of MS‐T1ρ by comparing the T1ρ value obtained using MS‐T1ρ with the reference value obtained using the standard single‐slice T1ρ mapping method. In vivo scans of 13 volunteers were acquired prospectively to validate the robustness of MS‐T1ρ.ResultsIn the phantom study, the T1ρ values obtained with MS‐T1ρ were in good agreement with the reference T1ρ values (R2 = 0.9991) and showed high consistency throughout all slices (coefficient of variation = 2.2 ± 2.43%). In the in vivo experiments, T1ρ maps were successfully acquired for all volunteers with no visually noticeable artifacts. There was no significant difference in T1ρ values between MS‐T1ρ acquisitions and fully sampled acquisitions for all brain tissues (p‐value > .05). In the intraclass correlation coefficient and Bland‐Altman analyses, the accelerated T1ρ measurements show moderate to good agreement to the fully sampled reference values.ConclusionThe proposed MS‐T1ρ solution allows for high‐resolution whole‐brain T1ρ mapping within 4 minutes and may provide a potential tool for investigating neural diseases.